Unit:
Κατεύθυνση Ανάπτυξη Νέων Φαρμάκων: Έρευνα, Κυκλοφορία και ΠρόσβασηLibrary of the School of Health Sciences
Author:
Maliagkas Paraskevas
Supervisors info:
Αναστάσιος Κόλλιας, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Κωνσταντίνος Ν. Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ηλίας Κοττέας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Φαρμακευτικές θεραπευτικές επιλογές για ασθενείς με συγγενείς καρδιοπάθειες
Translated title:
Pharmaceutical therapeutic options for patients with congenital heart diseases
Summary:
Background: Congenital heart diseases (CHD) are globally prevalent cardiac structural malformations, affecting approximately 1% of births. While CHD survival rates have improved in developed regions, challenges persist in developing areas. Pharmacological therapy for CHD has historically been empirical, necessitating ongoing research into evidence-based drug therapies and rational management of modern drugs. Aim: This research reviews pharmacological treatment options for CHD patients, analyzing applications, dosages, and side effects. The study assesses the level of evidence and recommendations for drug interventions in both pediatric and adult CHD populations. Methods: Employing a systematic review approach, this study aggregates data from reputable sources, primarily PubMed. The inclusion criteria encompassed articles, clinical trials and reviews published mainly from 2015 onwards. Results: Pharmacological therapies for CHD encompass a range of drug classes, each contributing to improved patient outcomes. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, potassium-sparing diuretics, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostaglandins all play vital roles in symptom management and survival rates for CHD patients. Conclusion: Pharmacological interventions are integral in CHD management, enhancing patient survival and symptom control. Continued research, especially in pediatric cases, is crucial to refine strategies and optimize drug regimens. Personalized approaches, informed by robust clinical trials, are vital for improving the lives and long-term outcomes of CHD patients.
Main subject category:
Health Sciences
Keywords:
Congenital heart disease, therapy
Number of references:
164
File:
File access is restricted only to the intranet of UoA.
Maliagkas Paraskevas MSc.pdf
2 MB
File access is restricted only to the intranet of UoA.
